Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial
Toniolo RA, Fernandes FBF, Silva M, Dias RDS, Lafer B
Journal of affective disorders · 32 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2016-11-20 · J Affect Disord · vol. 224 · págs. 69–75
- Editorial
- Elsevier BV
- Citado
- 49 citas · más que el 88% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 67 trabajos
- Acceso
- De pago
- Áreas de investigación
- Bipolar Disorder and Treatment · Treatment of Major Depression · Schizophrenia research and treatment
- Palabras clave
- creatine monohydrate, bipolar depression, adjunctive therapy, nutraceuticals, cognitive impairment, verbal fluency, neuropsychological assessment, bipolar disorder
- MeSH
- humans, creatine, antidepressive agents, combined modality therapy, double-blind method, cognition, bipolar disorder, neuropsychological tests, adult, middle aged, female, male, cognitive dysfunction
5 autores
- Ricardo Alexandre Toniolo🇧🇷Universidade de São Paulo
- Francy de Brito Ferreira Fernandes🇧🇷Universidade de São Paulo
- Michelle Silva🇧🇷Universidade de São Paulo
- Rodrigo da Silva Dias🇧🇷Universidade de São Paulo
- Beny Lafer🇧🇷 · autor de correspondenciaUniversidade de São Paulo
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Depressive episodes and cognitive impairment are major causes of morbidity and dysfunction in individuals suffering from bipolar disorder (BD). Novel treatment approaches that target clinical and cognitive aspects of bipolar depression are needed, and research on pathophysiology suggests that mitochondrial modulators such as the nutraceutical creatine monohydrate might have a therapeutic role for this condition.
Methods
Eighteen (N=18) patients with bipolar depression according to DSM-IV criteria who were enrollled in a 6-week, randomized, double-blind, placebo-controlled trial of creatine monohydrate 6g daily as adjunctive therapy were submitted to neuropsychological assessments (Wisconsin Card Sorting Test, Digit Span subtest of the Wechsler Adult Intelligence Scale-Third Edition, Stroop Color-Word Test, Rey-Osterrieth complex figure test, FAS Verbal Fluency Test) at baseline and week 6.
Results
There was a statistically significant difference between the treatment groups of the change on the total scores after 6 weeks in the verbal fluency test, with improvement in the group receiving adjunctive treatment with creatine. We did not find significant differences between the groups of the changes on other neuropsychological tests.
Limitations
Small sample and lack of a control group of healthy subjects.
Conclusions
Our trial, which was the first to investigate the cognitive effects of creatine monohydrate on bipolar depression, indicates that supplementation with this nutraceutical for 6 weeks is associated with improvement in verbal fluency tests in patients with this condition.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.